Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.